Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
99 hedge funds and large institutions have $372M invested in Insys Therapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 35 reducing their positions, and 9 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
126% more call options, than puts
Call options by funds: $4.81M | Put options by funds: $2.13M
89% more capital invested
Capital invested by funds: $197M → $372M (+$175M)
15% more funds holding
Funds holding: 86 → 99 (+13)
3% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$42.4M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$26.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.4M |
| 4 |
Renaissance Technologies
New York
|
+$5.44M |
| 5 |
TCM
Tamarack Capital Management
Carlsbad,
California
|
+$4.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$13.3M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$9.69M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$7.59M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$7.38M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$6.09M |
INSY Hedge Fund Activity: Q1 2014 in Review
99 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q1 2014, worth a combined $372M — up 89% from $197M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new INSY positions and 9 closed out — a net gain of 13 holders — while 36 added to existing stakes and 35 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $42.4M. The largest seller was BlackRock Advisors, cutting an estimated $13.3M.
- 99 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q1 2014, up from 86 in Q4 2013.
- Funds reported $372M of Insys Therapeutics, Inc. stock for Q1 2014, up 89% quarter-over-quarter.
- 22 funds opened new Insys Therapeutics, Inc. positions in Q1 2014 and 9 closed out, a net change of +13 holders.
- The largest Insys Therapeutics, Inc. buyer in Q1 2014 was Fidelity Investments, an estimated $42.4M added.
- The largest Insys Therapeutics, Inc. seller in Q1 2014 was BlackRock Advisors, an estimated $13.3M sold.
Based on aggregated 13F filings for Q1 2014.